China Fall Dampens GSK’s Emerging Markets Business
This article was originally published in PharmAsia News
GSK's emerging markets sales have again been hit by rising competition and the ongoing restructuring of its China business, but CEO Witty sees the dip as "reasonably temporary" and expects improvements in the fourth quarter.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.